- Psyched Wellness (PSYC) and its clinical research partner have commenced the next preclinical trial with AME-1
- AME-1 is the company’s proprietary extract from Amanita mushrooms
- This toxicity study of AME-1 will determine the dose(s) that will be administered for a subsequent long-term 90-day toxicity study
- Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
- Psyched Wellness (PSYC) opened trading at C$0.31 per share
Psyched Wellness (PSYC) and its clinical research partner KGK Science have commenced the next preclinical trial study with AME-1.
This new 14-day oral toxicity study of AME-1 will determine the dose(s) that will be administered for a subsequent long-term 90-day oral toxicity study.
The goal of this study is to determine dose-dependent effects along with determining the highest dose that is safe to use for a longer-term study. This is another key milestone in the further understanding of the effects of Psyched Wellness’ AME-1 extract under a scientific methodology in pursuit of a safe dose for human consumption.
“This represents another milestone event in the scientific study of AME-1. The results of this study will further increase the knowledge and further identify the physical and chemical properties of AME-1,” says Brian Tancowny, scientific advisor for Psyched Wellness.
“The pre-clinical trial we are currently conducting is part of a number of smaller studies that need to happen in a specific order and, when completed, will combine to provide the foundation off of which our future products will be developed.
As we embark on a new study or complete a study, we add significant value to the company as we are pioneering a path to market for AME-1 derived health and wellness products,” says Jeff Stevens, CEO of Psyched Wellness.
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
Psyched Wellness (PSYC) opened trading at C$0.31 per share.
